Document is current
Any future updates will be listed below
-
Authors
Deichaite, Ida https://orcid.org/0000-0001-8839-0573
Hopper, Austin
Krockenberger, Lena
Sears, Timothy J.
Sutton, Leisa
Ray, Xenia
Sharabi, Andrew
Navon, Ami
Sanghvi, Parag
Carter, Hannah
Moiseenko, Vitali
-
Funding
Funding for this research was provided by:
University of California, San Diego, Department of Radiation Medicine and Applied Sciences
National Institutes of Health (R01CA269919)
- License Information
-
More Information
Article History
Received: 13 June 2022
Accepted: 29 July 2022
First Online: 12 August 2022
Declarations
:
: This study was performed in accordance with federal, state and University policies, and approved by UCSD Human Research Protection Program IRB#200495. This protocol was reviewed and approved by the UCSD Human Research Protection Program in accordance with the requirements of the Code of Federal Regulations on the Protection of Human Subjects (45 CFR 46), including its relevant Subparts, for federally funded/support research studies. It was determined that a waiver of informed consent was granted for historic subjects (both clinical and research) as it meets the requirements outlined in 45 CFR 46.116(f).
: Not applicable.
: A.S. reports being a consultant/advisory board member for AstraZeneca, Varian Medical Systems, Primmune, and Jounce Therapeutics; reports receiving commercial research grants from Varian Medical Systems and Pfizer; holds ownership interest in Toragen Inc. outside of submitted work.
